A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

INTRODUCTION: Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to de...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979046/
https://ncbi.nlm.nih.gov/pubmed/24252402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3577
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak